10-Q: Turnstone Biologics to Merge with XOMA, Ceases Operations

Turnstone Biologics Corp. is set to merge with XOMA Royalty Corporation, discontinuing all clinical programs and reducing its workforce to three employees, with a potential liquidation if the merger fails.

Summary

• Turnstone Biologics Corp. entered into a Merger Agreement with XOMA Royalty Corporation on June 26, 2025, for an acquisition at $0.34 per share plus one Contingent Value Right (CVR).
• The company has discontinued all clinical studies, including TIDAL-01, and nonclinical research and manufacturing activities, leading to a significant reduction in research and development expenses.
• The workforce has been reduced to 3 employees as of June 30, 2025, with further reductions anticipated as the merger progresses.
• The Board has concluded that the company has no standalone business plan and will pursue dissolution and liquidation if the merger is not consummated.
• Turnstone is non-compliant with Nasdaq's minimum bid price requirement and has been granted an extension until September 22, 2025, with a reverse stock split planned to regain compliance.
• Net loss for the three months ended June 30, 2025, was $5.49 million, a significant decrease from $21.30 million for the same period in 2024.
• Net loss for the six months ended June 30, 2025, was $17.30 million, down from $40.93 million for the same period in 2024.
• Research and development expenses decreased by 99.4% to $0.17 million for the three months ended June 30, 2025, and by 86.6% to $4.53 million for the six months ended June 30, 2025.
• General and administrative expenses increased by 25.6% to $5.39 million for the three months ended June 30, 2025, and by 10.9% to $10.20 million for the six months ended June 30, 2025, primarily due to merger and restructuring costs.
• Cash and cash equivalents decreased to $16.69 million as of June 30, 2025, from $28.93 million as of December 31, 2024.
• The Loan and Security Agreement with Banc of California for a $20 million revolving credit facility was terminated on May 14, 2025, with no amounts drawn, after the company failed to meet a $40 million new funding covenant by March 31, 2025.
• An Asset Purchase Agreement was signed with Moffitt Cancer Center to sell TIDAL-01 program assets for approximately $3.0 million, with $1.8 million placed in escrow, contingent on the merger closing.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative as the company is effectively winding down its operations and pursuing a merger that offers limited upside to shareholders, with a high risk of liquidation if the merger fails. The significant reduction in R&D expenses and net loss is a result of ceasing operations, not improved performance.

Positives

• Net loss significantly decreased to $5.49 million for Q2 2025 from $21.30 million in Q2 2024, and to $17.30 million for H1 2025 from $40.93 million in H1 2024, primarily due to the discontinuation of costly R&D programs.
• Research and development expenses saw a drastic reduction of 99.4% in Q2 2025 and 86.6% in H1 2025, reflecting successful cost containment measures.
• The termination of the $20 million revolving credit facility with Banc of California occurred without any amounts having been drawn or significant termination fees incurred.
• The merger agreement with XOMA provides a defined exit strategy for shareholders, including a cash component and potential contingent value rights.

Negatives

• The company has discontinued all clinical studies and nonclinical research and manufacturing activities, effectively ceasing its core biotechnology operations.
• The Board has concluded that there is no standalone business plan, and the only alternative to the merger is dissolution and liquidation, indicating a failure of the company's original strategic direction.
• Turnstone Biologics is non-compliant with Nasdaq's minimum bid price requirement and faces potential delisting if it does not regain compliance by September 22, 2025, despite planning a reverse stock split.
• Cash and cash equivalents declined significantly to $16.69 million as of June 30, 2025, from $28.93 million at year-end 2024, reflecting ongoing cash burn.
• The company failed to meet a covenant requiring $40 million in new funding by March 31, 2025, which led to the termination of its credit facility.
• General and administrative expenses increased due to costs associated with the merger and employee restructuring, despite the overall reduction in operations.
• The Contingent Value Right (CVR) is a contractual right only, not transferable (except in limited circumstances), not registered with the SEC, has no voting or dividend rights, accrues no interest, and may expire valueless if CVR proceeds are not received within one year post-merger closing.

Risks

• Failure to complete the merger with XOMA within the expected timeframe or at all could have a material adverse effect on the business, operating results, financial condition, and share price.
• Significant transaction costs related to the merger have been incurred or may be payable even if the merger is not consummated.
• Management's focus has been diverted to the merger, potentially hindering the pursuit of other strategic opportunities if the merger fails.
• Disruptions to business relationships with partners, suppliers, and employees could continue or accelerate if the merger is not consummated.
• The company's share price may fluctuate significantly based on announcements regarding the merger or market perceptions of its completion likelihood, potentially declining if the merger is not completed.
• Unforeseen and unexpected expenses could cause the company's net cash to fall below the applicable threshold, leading to a failure of a merger closing condition.
• If the merger is not consummated, the company will need to seek stockholder approval for the Asset Sale to Moffitt, and if not obtained, the $1.8 million held in escrow would be released to Moffitt, not stockholders.
• Stockholders may not receive any payment on the Contingent Value Right (CVR), and the CVR may expire valueless, as payments are contingent on specific events and a one-year timeframe post-merger.
• Stockholder litigation could prevent or delay the consummation of the merger or otherwise negatively impact the business, operating results, and financial condition.
• If the merger is not consummated, the Board intends to pursue a dissolution and liquidation, where the amount of cash available for distribution to stockholders will depend on timing and reserves for commitments and contingent liabilities, potentially leading to a loss of all or a significant portion of investment.

Future Outlook

The company expects the merger with XOMA Royalty Corporation to close in the third quarter of 2025. If the merger is not consummated, the Board intends to pursue a dissolution and liquidation. Existing cash and cash equivalents are believed to be sufficient to fund planned expenditures until the anticipated merger closing. The company anticipates a continued decrease in other income due to declining cash balances.

Management Comments

• "Our Board has concluded that we do not have a standalone business plan and our only plan in the absence of a sale or merger is to pursue a dissolution and liquidation."
• "We expect that the Merger will close in the third quarter of 2025."
• "We believe that our existing cash and cash equivalents will enable us to fund our planned operating expenses and capital expenditures through our anticipated closing of the Merger in the third quarter of 2025."

Industry Context

This announcement reflects a significant shift for Turnstone Biologics, moving from a clinical-stage biotechnology company focused on TIL therapies to a company being acquired by a royalty corporation. This indicates a failure to successfully advance its pipeline to commercialization, a common challenge in the high-risk, high-reward biotech industry. The acquisition by a royalty company suggests a monetization of remaining assets and intellectual property rather than continued drug development, aligning with a trend where distressed biotech assets are acquired for their potential future revenue streams, however contingent. The drastic reduction in workforce and discontinuation of programs highlight the intense capital requirements and high attrition rates in drug development, particularly for novel therapies like TILs.

Comparison to Industry Standards

• Turnstone's discontinuation of all clinical studies and pivot to a merger with a royalty company contrasts sharply with successful biotech firms like Gilead Sciences or Amgen, which consistently advance multiple drug candidates through clinical phases to market.
• The company's accumulated deficit of $264.9 million and consistent net losses since inception are typical for early-stage biotech, but the inability to secure further funding or partnerships to continue development, as evidenced by the termination of the Banc of California credit facility due to unmet funding covenants, indicates a failure to meet industry expectations for sustained R&D investment.
• The sale of the TIDAL-01 program assets to Moffitt Cancer Center for $3.0 million and the termination of the Alliance Agreement, rather than a successful commercialization or a high-value licensing deal, suggests a distressed asset sale, unlike the multi-billion dollar deals seen for promising oncology assets from companies like Seagen (acquired by Pfizer) or Mirati Therapeutics (acquired by Bristol Myers Squibb).
• The CVR structure, offering a small cash amount and highly contingent future payments, is a common mechanism in distressed asset sales or mergers where the acquiring entity seeks to limit upfront risk, unlike more robust acquisition premiums seen in successful biotech exits.
• The Nasdaq delisting risk due to sub-$1.00 share price is a common issue for small-cap biotechs that fail to achieve clinical or commercial milestones, contrasting with established companies that maintain listing compliance through strong financial performance and pipeline progress.

Stakeholder Impact

• Shareholders: Will receive $0.34 cash per share plus a contingent value right (CVR) if the merger closes. Face significant risk of losing investment if the merger fails and the company liquidates. CVR is highly speculative and may expire valueless.
• Employees: Workforce has been drastically reduced to 3 employees, with further reductions expected, indicating significant job losses.
• Customers/Partners: Clinical programs have been discontinued, impacting potential future patients and existing collaboration agreements (e.g., Moffitt Cancer Center, which is now acquiring assets related to TIDAL-01).

Next Steps

• Complete the merger with XOMA Royalty Corporation, anticipated to close in the third quarter of 2025.
• Implement a reverse stock split to regain compliance with Nasdaq's Minimum Bid Price Requirement by September 22, 2025.
• Continue reducing workforce as the merger completes.
• If the merger is not consummated, the Board intends to pursue a dissolution and liquidation.
• Release of $1.8 million escrow amount to the company following the consummation of the merger.

Key Dates

Recommendation

The company is effectively liquidating its operations through a merger with XOMA Royalty Corporation, offering a fixed cash price of $0.34 per share plus a highly contingent CVR that may expire valueless. All clinical programs have been discontinued, and the company has no standalone business plan. If the merger fails, the Board intends to pursue dissolution and liquidation, which could result in shareholders losing all or a significant portion of their investment. Given the cessation of core operations, the high uncertainty of the CVR, and the significant downside risk if the merger does not close, a seasoned investor would recommend selling to realize the cash component and avoid further exposure to the liquidation risk.

Keywords

Biotechnology, Merger, XOMA, SEC Filing, 10-Q, Financial Results, Liquidation, Nasdaq Delisting, Contingent Value Right, CVR, Workforce Reduction, Clinical Trials Discontinuation, Asset Sale, Moffitt Cancer Center, TIDAL-01